Capital Fund Management (CFM)
EGRX

Capital Fund Management (CFM)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,500
Closed -$328K – 2021
2017
Q3 		$328K Buy
+5,500
New +$333K ﹤0.01% 1299

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Capital Fund Management (CFM)'s EGRX Position: Q4 2020 in Review

Capital Fund Management (CFM) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 18,644 shares — an estimated $792K sold.

Capital Fund Management (CFM) first reported a position in EGRX in Q3 2016 and held it in 11 quarters. The position peaked at $7.49M in Q3 2017. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Capital Fund Management (CFM) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 18,644 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $792K.
  • Capital Fund Management (CFM) first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 11 quarters.
  • Capital Fund Management (CFM)'s Eagle Pharmaceuticals, Inc. position peaked at $7.49M in Q3 2017.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2020, filed 12 Feb 2021.